The agreement is subject to other shareholders delivering their signatures and provides for customary conditions to closing.
The transaction was completed by Lincoln International, a mid-market investment bank, who acted as the exclusive financial advisor to Schwabe Pharmaceuticals and Nature’s Way, working directly with the board of directors and senior management teams of both companies.
The combination of these organizations is expected to create an unsurpassed portfolio of clinically validated natural products and ingredients.
Dirk Reischig, chairman and CEO of Dr Willmar Schwabe Pharmaceuticals, said: “We are very delighted that Enzymatic Therapy joins the Schwabe group of companies. We do believe that the complementary product portfolios and marketing know-how of Enzymatic Therapy and Nature’s Way will significantly strengthen our presence in the US market, which is one of Schwabe’s strategic key markets for future growth.
“The joined forces of Enzymatic Therapy, Nature’s Way and Schwabe Pharmaceuticals will therefore contribute significantly to consumers in the US and abroad in achieving the best possible health and quality of life.”
Rory Mahony, CEO of Nature’s Way, said: “We look forward to leveraging the knowledge and expertise resident in our companies and to further enhance the significant business growth that both Nature’s Way and Enzymatic Therapy have enjoyed over the past several years. We believe the dedication of the companies to the development of quality products will benefit our customers in many ways.”